ASH Data Show Fixed-Duration Epcoritamab Yields Durable First-Line Responses in DLBCL and FL

Overview

• In EPCORE NHL-2 Arm 1, epcoritamab plus R-CHOP in newly diagnosed DLBCL achieved a 98% overall response rate and 85% complete response rate with approximately 44 months of follow-up, with most complete remissions ongoing at three years.
• EPCORE NHL-2 Arm 8 in elderly, anthracycline‑ineligible patients showed a 93% response rate and 86% complete responses with two‑year response durability of 79% and 95% minimal residual disease negativity among evaluable patients.
• Safety across cohorts remained consistent with prior experience, including frequent mostly low‑grade cytokine release syndrome, substantial infections (for example, grade ≥3 infections in about one‑third of Arm 8), and rare fatal events leading to treatment discontinuation in a minority.
• EPCORE DLBCL-3 reported epcoritamab monotherapy responses in newly diagnosed, frail patients (73% overall, 62% complete), with one‑year progression‑free and overall survival estimates of 54% and 65%, and largely low‑grade cytokine release syndrome and manageable neurotoxicity.
• For first‑line follicular lymphoma, epcoritamab plus bendamustine/rituximab produced three‑year estimates for duration of response, progression‑free survival, and overall survival of 87%, 83%, and 96%, and separate ASH‑presented Phase 3 data in relapsed FL showed epcoritamab plus R2 outperformed R2 and underpinned the recent U.S. approval.